These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30982469)

  • 1. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
    Gonzalez-Exposito R; Semiannikova M; Griffiths B; Khan K; Barber LJ; Woolston A; Spain G; von Loga K; Challoner B; Patel R; Ranes M; Swain A; Thomas J; Bryant A; Saffery C; Fotiadis N; Guettler S; Mansfield D; Melcher A; Powles T; Rao S; Watkins D; Chau I; Matthews N; Wallberg F; Starling N; Cunningham D; Gerlinger M
    J Immunother Cancer; 2019 Apr; 7(1):101. PubMed ID: 30982469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
    Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
    Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
    [No Abstract]   [Full Text] [Related]  

  • 3. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
    Segal NH; Melero I; Moreno V; Steeghs N; Marabelle A; Rohrberg K; Rodriguez-Ruiz ME; Eder JP; Eng C; Manji GA; Waterkamp D; Leutgeb B; Bouseida S; Flinn N; Das Thakur M; Elze MC; Koeppen H; Jamois C; Martin-Facklam M; Lieu CH; Calvo E; Paz-Ares L; Tabernero J; Argilés G
    Nat Commun; 2024 May; 15(1):4091. PubMed ID: 38750034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PET-Tracer
    Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
    Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
    Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
    Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the Design and Geometry of T Cell-Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer.
    Elsayed A; Plüss L; Nideroest L; Rotta G; Thoma M; Zangger N; Peissert F; Pfister SK; Pellegrino C; Dakhel Plaza S; De Luca R; Manz MG; Oxenius A; Puca E; Halin C; Neri D
    Mol Cancer Ther; 2024 Jul; 23(7):1010-1020. PubMed ID: 38638035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
    Osada T; Hsu D; Hammond S; Hobeika A; Devi G; Clay TM; Lyerly HK; Morse MA
    Br J Cancer; 2010 Jan; 102(1):124-33. PubMed ID: 19953093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
    Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
    Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.
    Stoltzfus CR; Sivakumar R; Kunz L; Olin Pope BE; Menietti E; Speziale D; Adelfio R; Bacac M; Colombetti S; Perro M; Gerner MY
    Front Immunol; 2021; 12():726492. PubMed ID: 34421928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining
    Van De Vyver AJ; Weinzierl T; Eigenmann MJ; Frances N; Herter S; Buser RB; Somandin J; Diggelmann S; Limani F; Lehr T; Bacac M; Walz AC
    Mol Cancer Ther; 2021 Feb; 20(2):357-366. PubMed ID: 33298591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
    Wu Z; Guo HF; Xu H; Cheung NV
    Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
    Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.
    Meller B; Rave-Fränck M; Breunig C; Schirmer M; Baehre M; Nadrowitz R; Liersch T; Meller J
    Strahlenther Onkol; 2011 Feb; 187(2):120-6. PubMed ID: 21271227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer.
    Eftekhar E; Naghibalhossaini F
    Mol Biol Rep; 2014 Jan; 41(1):459-66. PubMed ID: 24293105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.